FinnGen Selects Olink to Accelerate Leading Population Health Study

Receive instant alerts when news is published about your stocks. Claim your one week free trial for StreetInsider Premium here.

UPPSALA, Sweden, June 13, 2022 (GLOBE NEWSWIRE) — Olink Holding AB (publ) (Nasdaq:OLK) today announced that FinnGen in Finland will use Olink technology to provide detailed proteomics data to improve understanding of human health.

FinnGen, is a large-scale academic/industrial research collaboration in Finland with the goal of collecting and analyzing genomic and health data from 500,000 Finnish biobank participants. This is one of the very first personalized medicine projects aimed at providing new, clinically relevant information while building a world-class resource that can be applied to future studies.

The FinnGen study has so far identified more than 400 new disease-associated loci where the associated gene variant is enriched in the Finnish population. Olink was chosen by FinnGen to provide comprehensive proteomic profiling of up to 2500 individuals in the study. These results can serve as a basis for further functional studies in combination with high-quality proteomics, offering the potential for new insights into disease mechanisms.

“We welcome Olink on board. Olink Proteomics cutting-edge technology was selected after considering high data quality, specificity and its global recognition by large-scale proteomics projects such as the UKBB as a as proteomics technology of the future. Olink’s platform will provide detailed and comprehensive proteomics data covering all major biological pathways and processes. This data will be generated from a subset of study participants who carry certain of these medically and clinically interesting genetic variants,” said Aarno Palotie, Scientific Director FinnGen of the Finnish Institute of Molecular Medicine (FIMM), University of Helsinki. “Olink can help us lay the foundation for health innovations and personalized treatments. We hope our study will inspire researchers and companies around the world to join the journey to personalized healthcare.

FinnGen brings together Finnish biobanks, university hospitals and their respective universities, the Finnish Institute for Health and Welfare (THL), the Blood Service of the Finnish Red Cross, Finnish biobanks – FINBB, pharmaceutical companies leading international organizations and hundreds of thousands of Finnish citizens.

“We are very happy to be part of the FinnGen project. The fact that Olink was selected by FinnGen certainly underscores the confidence in Olink and our proprietary Proximity Extension Assay (PEA) technology, which combines high-throughput, high-quality protein-level measurements into reliable data to uncover actionable insights that are key to achieving breakthroughs in disease prevention, diagnosis and treatment,” said Henk Mouthaan, Vice President Sales and Marketing EMEA, Olink Proteomics.

Olink’s platform based on proprietary PEA technology is developed and optimized to detect and identify with very high specificity 3000 proteins across all major biological pathways for a wide range of sample matrices such as serum and plasma.

Contact Investor Jan Medina, CFAVP Investor Relations & Capital MarketsMobile: +1 617 802 4157[email protected]

Media Contact Andrea PranderCorporate Communications ManagerMobile: +46 768 775 275[email protected]

About FinnGenThe FinnGen study, launched in Finland in 2017, is a unique study that combines genome information with digital healthcare data. The FinnGen study plans to analyze up to 500,000 samples collected by a nationwide network of Finnish biobanks. The project aims to improve human health through genetic research and ultimately to identify new therapeutic targets and new diagnostics for the treatment of many diseases. It produces near-complete genome variant data from the 500,000 participants using genotyping and GWAS imputation and will use the extensive longitudinal National Health Registry data available on all Finns. FinnGen is an exceptionally broad academic-pharma partnership with considerable public financial support from Business Finland (formerly Tekes). The University of Helsinki is the organization responsible for the study.

About OlinkOlink Holding AB (Nasdaq:OLK) is a company dedicated to accelerating proteomics in collaboration with the scientific community, in multiple disease areas, to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services that are deployed across leading pharmaceutical companies and leading clinical and academic institutions to deepen understanding of human biology in real time and drive 21st century healthcare through science. actionable and impactful. The company was founded in 2016 and is well established in Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.

Forward-looking statementsThis release may contain forward-looking statements within the meaning of applicable securities laws, including the United States Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding strategy, business plans and direction of Olink. The words “may”, “will”, “could”, “should”, “should”, “expect”, “plan”, “anticipate”, “intend”, “believe”, ” estimates”, “predicts”, “project”, “potential”, “pursue”, “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. All forward-looking statements contained in this press release are based on management’s current expectations and beliefs as of the date hereof and are subject to a number of important risks, uncertainties and factors that may cause actual events or results differ materially from those expressed or implied. by any forward-looking statements contained in this press release, including, without limitation, those relating to Olink’s business, operations, supply chain, strategy, objectives and anticipated timelines, including including for the delivery of Olink Explore 3072 and the expansion of the Explore platform, competition and other risks identified in the section titled “Risk Factors” in Olink’s registration statement on Form F- 1, as amended (File No. 333-253818) filed with the United States Securities and Exchange Commission (SEC) and in the other filings, reports and documents that Olink files from time to time with the SEC. Olink expressly disclaims any obligation to update any forward-looking statements contained in this release to reflect any change in its expectations with respect thereto or any change in events, conditions or circumstances on which such statement is based, except as required by law or regulations require it.

main logo

Source: Olink Proteomics AB

Comments are closed.